Gilead, Merck say once-weekly HIV pill meets Phase 3 endpoint in ISLEND trials

Merck
Gilead Sciences

Merck

MRK

0.00

Gilead Sciences

GILD

0.00
  • Gilead disclosed positive topline Phase 3 results for an investigational once-weekly oral HIV tablet combining islatravir with lenacapavir.
  • ISLEND-1, a blinded switch study, met its main goal, supporting comparable viral control versus Biktarvy.
  • ISLEND-2, an open-label switch study, also met its main goal, showing comparable performance versus standard daily regimens.
  • Safety was broadly in line with comparators, with no new concerns flagged.
  • Detailed findings will be submitted for presentation at a future scientific congress, ahead of planned global regulatory filings.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260608276598) on June 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.